Founding Director, Massachusetts Technology Transfer Center
Founder, The Haul Company
Managing Partner at Pappas Ventures
President & CEO, Indiana Biosciences Research Institute
Nobel Laureate, Professor of Biology, Caltech
CEO and Fund Manager, Renaissance Venture Capital Fund
Head of global research and development at Life Technologies
Acadia Pharmaceuticals revealed late-stage clinical data this week that could support bringing its drug for psychosis to a broader group of patients.
The Acadia (NASDAQ: ACAD) drug pimavanserin (Nuplazid) is currently approved for treating psychosis associated with Parkinson’s disease.... Read more »
It’s been a roller-coaster year for those hoping for new drugs to treat Alzheimer’s disease, a leading cause of death with rising treatment costs and no clear answer yet as to its cause.
Clearing proteins, such as amyloid and tau, was... Read more »
Biogen revealed detailed results from its Alzheimer’s trial to a jam-packed room of eager conference attendees this week—and while some described it as a major advance in the field, others were less convinced.
Samantha Budd Haeberlein, Biogen’s vice president of clinical... Read more »
It’s the “era of neuroscience”; an industry “turning point”; and “an amazing time”—superlatives were flowing freely as the 12th annual Clinical Trials on Alzheimer’s Disease congress (CTAD) kicked off in rainy San Diego late Wednesday afternoon.
The atmosphere felt thick with... Read more »
Scientists gathered this week in San Diego at the annual Clinical Trials on Alzheimer’s Disease Congress are focused on ways to treat the neurodegenerative disease, a task that continues to vex those working to develop potential medicines. Others are working on... Read more »
Two venture-backed startups that have developed technologies intended to speed up the drug discovery and development process are combining those tools in a bid to achieve their goals together.
San Francisco-based Atomwise has developed deep learning techniques for use in structure-based... Read more »
[Updated 12/4/19, 4:01 p.m. ET. See below.] Veracyte, a company whose tests help physicians make treatment decisions, is adding technology from NanoString to the fold to expand its diagnostic capabilities.
South San Francisco-based Veracyte (NASDAQ: VCYT) announced Tuesday... Read more »
Neurocrine Biosciences is paying $30 million cash and taking a $20 million equity stake in Xenon Pharmaceuticals to license a clinical-stage epilepsy drug and collaborate on other potential treatments for the seizure-causing brain disorder.
The Xenon (NASDAQ: XENE) deal is the... Read more »
La Jolla Pharmaceutical is turning its focus to its lone FDA-approved product and another one in the pipeline after an experimental drug for a rare blood disease failed a late-stage study.
On Monday, La Jolla Pharma (NASDAQ: LJPC) said it... Read more »
Phoenix Molecular Designs, a biotech developing kinase inhibitors to treat cancer, has brought in an undisclosed amount of financing—boosting its total seed funding raised to $12 million.
The San Diego-based biotech says the proceeds will help fund the Phase 1/1b clinical... Read more »
In startup world these days, the word “biotech” is increasingly accompanied by “computational” and two, two-letter initialisms: AI and ML.
Those tools—artificial intelligence and machine learning, respectively—have been around for decades, but in recent years have become faster and cheaper, accelerating... Read more »
Bristol-Myers Squibb this week completed its acquisition of Celgene, a $74 billion deal that creates a pharmaceutical juggernaut. And all it took was the largest asset sale ever required by federal antitrust regulators.
As the Federal Trade Commission reviewed Bristol’s (NYSE:... Read more »
Drug pricing debates and uncertainty associated with Brexit are the issues most likely to keep biopharmaceutical executives awake at night. Nevertheless, senior figures remain optimistic about the industry’s prospects in 2020. These are among the major findings of a survey of... Read more »
Lung injuries connected to the use of electronic cigarettes have topped 2,000 and killed 40 people, according to the Centers for Disease Control and Prevention.
It’s still unclear whether the cases are tied to legally sold products or devices modified by... Read more »
The list of activities our smartphones can control grows daily. Transfer money? It’s simple. Order groceries? That, too. Turn off the bedroom lights? Check.
How about contraception?
Advancing new forms of birth control is a central focus at Daré Bioscience (NASDAQ:... Read more »
Another of the biopharma startups created as part of a collaboration between San Diego investment firm Avalon Ventures and GlaxoSmithKline has been acquired—but not by GSK.
Instead, the company, Calporta Therapeutics, is being absorbed by Merck (NYSE: MRK), which is... Read more »
Earlier this year, Avidity Biosciences and Eli Lilly began a partnership to develop new drugs based on the biotech’s technology for delivering genetic material to cells. On Wednesday, Lilly was among a group of investors that joined a $100 million financing... Read more »
A Roche drug in development as a treatment for spinal muscular atrophy achieved the main goals of a key study, helping to build the case that the drug could challenge a Biogen therapy already approved for the rare disorder.
Roche announced... Read more »
These are heady times for neuroscience research. Startups developing new approaches to brain disorders are raising money to advance their discoveries toward clinical trials. One failed neuro drug is getting another shot.
On Nov. 19 in San Francisco, we’ll... Read more »
Danish diabetes giant Novo Nordisk took another step this week in its efforts to establish a presence in nonalcoholic steatohepatitis, or NASH, a metabolic disorder closely related to diabetes that is anticipated to become the leading cause of liver transplants in... Read more »
During the state of the union address this year, President Trump pledged to end HIV transmission within the next decade. A key part of that plan is an HIV prevention drug made by Gilead Sciences. That drug has now become the... Read more »
AstraZeneca says it will establish centers for drug research and artificial intelligence development in China. The pharmaceutical giant has also set up a $1 billion fund to foster biotech innovation in that country.
The move—which was announced at the China International... Read more »
From Our Partners · Special Report
Advice for funding and future transformational opportunities
Xconomy Insight · Special Report
Insights, wisdom, and inspiration on what it takes
From Our Editors · Special Report
Key indicators & expert insight from industry leaders
Xconomy
Co-Founder and Executive Chairman, CleanTECH San Diego
Professor of Computer Graphics, UC San Diego
Professor of Chemistry, Scripps Research Institute
Head, Janssen Healthcare Innovation
Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
Founding Director of Calit2
Senior health advisor for Esri
Associate Vice Chancellor, UCSD
President and CEO, Molecular Assemblies; strategic advisor, Microdermis; co-founder, board member, Genoa Pharmaceuticals
Co-founder and Managing Partner, TVC Capital
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
